Annals of Emergency Medicine
Volume 54, Issue 3 , Pages 342-343 , September 2009

A Hundred (and One) Graphs Tell Only Part of the Story

  • Robert Silbergleit, MD

      Affiliations

    • Corresponding Author InformationAddress for correspondence: Robert Silbergleit, MD, University of Michigan Department of Emergency Medicine, Neuro Emergency Research, 24 Frank Lloyd Wright Dr, Lobby H, Suite 3100, Ann Arbor, MI 48106; 734-232-2142, fax 734-232-2122

References 

  1. NINDS rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581–1588
  2. Ingall TJ, O'Fallon WM, Asplund K, et al. Findings from the reanalysis of the NINDS Tissue Plasminogen Activator for Acute Ischemic Stroke Treatment trial. Stroke. 2004;35:2418–2424
  3. Saver JL, Yafeh B. Confirmation of tPA treatment effect by baseline severity-adjusted end point reanalysis of the NINDS-tPA stroke trials. Stroke. 2007;38:414–416
  4. Savitz SI, Lew R, Bluhmki E, et al. Shift analysis versus dichotomization of the modified Rankin Scale outcome scores in the NINDS and ECASS-II trials. Stroke. 2007;38:3205–3212
  5. Hoffman JR, Schriger DL. A graphic reanalysis of the NINDS trial. Ann Emerg Med. 2009;54:329–336
  6. Yeatts S, Palesch Y, Silbergleit R. Characterizing the statistical properties of the sliding dichotomy. Acad Emerg Med. 2009;16:S15
  7. Lindley RI, Wardlaw JM, Sandercock PA. Alteplase and ischaemic stroke: have new reviews of old data helped?. Lancet Neurol. 2005;4:249–253
  8. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768–774
  9. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317–1329

 Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article that might create any potential conflict of interest. See the Manuscript Submission Agreement in this issue for examples of specific conflicts covered by this statement. Dr. Silbergleit has previously been a coinvestigator on a study funded by the Michigan Department of Community Health on the use of tPA as a treatment for ischemic stroke. He has coauthored studies and commentaries on this topic. He has served on NIH review panels and workshops involving acute stroke research. He has never received industry support for work on tPA, has not received payments for speaking about tPA, and has not received fees providing expert testimony in malpractice cases involving tPA.

 Reprints not available from the authors.

 Supervising editor: Donald M. Yealy, MD

PII: S0196-0644(09)01255-4

doi: 10.1016/j.annemergmed.2009.07.010

Annals of Emergency Medicine
Volume 54, Issue 3 , Pages 342-343 , September 2009

Article Tools

* Image Usage & Resolution